This website uses cookies. They allow us to optimize your browsing experience and also help us to understand how you use our site. By continuing to use this website, you accept our use of cookies. Cookie information page
Close

Safe Harbor Statement

The following Safe Harbour Statement applies to all our press releases.

"This press release contains statements which address such key issues as AkzoNobel’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies."